Business
Isodiol International Inc. - Delay In Filing Audited Financial Statements - Obtains Management Cease Trade Order from BCSC
Isodiol International Inc. - Delay In Filing Audited Financial Statements - Obtains Management Cease Trade Order from BCSC.
About this update from Isodiol International Inc
[{"type":"text","content":"\nVANCOUVER, British Columbia, July 30, 2019 (GLOBE NEWSWIRE) -- Isodiol International Inc. (CSE: ISOL) (OTCQB:ISOLF) (FSE: LB6B.F) (the “Company” or “Isodiol”), today announces a delay in the filing of its audited annual financial statements, related management’s discussion and analysis and supporting officer certificates for the financial year ended March 31, 2019 (the “Filings”).  The Filings are required to be made with the relevant securities regulatory authorities on or before July 29, 2019.\n The anticipated delay of its Filings is a result of delays in getting access to accounting information pursuant to dispositions of subsidiaries for which the Company no longer has management influence over. The Company notes that such delays have been resolved and the Company is now in the final stages of the audit and anticipates completing its Filings before August 16, 2019. The Company has obtained a management cease trade order from the relevant securities regulators as contemplated by National Policy 12-203 Management Cease Trade Orders of the Canadian Securities Administrators.  The Company will comply with the requirements of the alternative information guidelines set out in the National Policy.   The Company is not subject to any insolvency proceedings. The Company also announces the departure of Kevin Swadish, Chief Revenue Officer and Patrick Ogle as a Director and Chief Operating Officer of the Company. Follow Our Corporate Updates On Facebook at www.facebook.com/IsodiolInternationalInc/, on Twitter @Isodiolintlinc, and on Instagram @isodiol. About Isodiol International Inc. Isodiol International Inc. is focused on the nutritional health benefits that are derived from hemp and is a product development, sales, marketing and distribution company of hemp-based Consumer Packaged Goods (CPG) and solutions. Isodiol has commercialized a 99%+ pure, naturally isolated CBD, including micro-encapsulations, and nano-technology for quality consumable and topical skin care products. The Company received approval for its CBD as an Active Pharmaceutical Ingredient (API) for use in Finished Pharmaceutical Products (FPPs), as was announced on April 26, 2018.  Isodiol’s growth strategy includes the development of over-th...